MSH2 and lymphoma: All the recipients of MSH2-/- Lin- cells and 90% of MSH2-/- LSK cells recipients developed thymic lymphomas, while no lymphomas were observed in recipients of CLP or CMP cells up to 9 months (Fig 1B).